OMER
Omeros Corporation
NASDAQ · Healthcare · Biotechnology · US
$18.95
−0.84%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
8.5x
EV/EBITDA
9.7x
Market Cap
$1.37B
MomentumView details →
1D Return
−0.84%
YTD Return
+10.94%
RSI (14)
71.4
ValuationView details →
P/E (Fwd)
8.5x
EV/EBITDA
9.7x
Market Cap
$1.37B
RSI (14)
71.4
MomentumView details →
1D Return
−0.84%
YTD Return
+10.94%
SummaryUpdated Jun 1, 2026
Omeros Corporation (NASDAQ:OMER) is a commercial-stage biopharmaceutical company founded in 1994 and headquartered in Seattle, Washington. The company went public in 2009 and focuses on discovering, developing, and commercializing innovative therapeutics for rare diseases, particularly those involving complement-mediated disorders, inflammatory conditions, and addictive behaviors. Omeros has evolved from a research-stage company to having one commercialized product generating royalty revenue, while advancing multiple late-stage clinical programs targeting significant unmet medical needs in orphan disease markets.
Similar companies
Latest newsMore news →
Omeros reduced its convertible debt after the quarter ended.23d agoOmeros reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for TA-TMA, and generated positive operating cash flow.23d agoOmeros Corporation appointed Joseph Schocken as a director, effective August 12, 2026, and granted him a stock option to purchase 30,000 shares of common stock on the date of appointment.23d ago